Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysis

Mariani, Stefania; Ventriglia, Mariacarla; Simonelli, Ilaria; Donno, Silvia; Bucossi, Serena; Vernieri, Fabrizio; Melgari, Jean Marc; Pasqualetti, Patrizio; Rossini, Paolo Maria; Squitti, Rosanna

doi:10.1016/j.neurobiolaging.2012.05.015

Cited by 65 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zinc has antioxidant activity and is a constituent of Cu +2 /Zn +2 -SOD (Jiménez-Jiménez et al, 1998). The results of studies with CSF levels of iron and copper are controversial (Table 3), but a recent meta-analysis showed similar values in PD patients to controls (Mariani et al, 2013), thus suggesting that these metals are not useful as markers of PD.…”

Section: Oxidative Stress Markersmentioning

confidence: 99%

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.

show abstract

Section: Oxidative Stress Markersmentioning

confidence: 99%

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…In fact, at the same concentrations of Fe and of Tf-saturation, women had a lower probability of having PD. Moreover, in our recent meta-analysis [12], we found no J U…”

Section: Discussionmentioning

confidence: 80%

“…The subject sample analyzed in the current study partially overlaps (65.5%) the one of a previous study of ours [12].…”

Section: Subjectsmentioning

confidence: 83%

“…A c c e p t e d M a n u s c r i p t 10 significant sex effect on Fe circulating levels, even though the replication study reported in the same article [12], pointed out that women had higher Tf serum levels. Therefore, we confirmed a potential role of sex in modifying Fe biological variables in PD.…”

Section: S T a C C E P T E Dmentioning

confidence: 91%

“…However, a recent meta-analysis revealed the absence of increased concentrations of systemic Fe in the serum of PD patients [12], confirming the high heterogeneity of results. This heterogeneity was also reported by numerous studies investigating the association between genes related to Fe metabolism and PD.…”

mentioning

confidence: 82%

See 2 more Smart Citations

Association between sex, systemic iron variation and probability of Parkinson's disease

Mariani

Ventriglia

Simonelli

et al. 2015

International Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

Parkinson’s disease therapy: what lies ahead?

et al. 2023

View full text Add to dashboard Cite

The worldwide prevalence of Parkinson’s disease (PD) has been constantly increasing in the last decades. With rising life expectancy, a longer disease duration in PD patients is observed, further increasing the need and socioeconomic importance of adequate PD treatment. Today, PD is exclusively treated symptomatically, mainly by dopaminergic stimulation, while efforts to modify disease progression could not yet be translated to the clinics. New formulations of approved drugs and treatment options of motor fluctuations in advanced stages accompanied by telehealth monitoring have improved PD patients care. In addition, continuous improvement in the understanding of PD disease mechanisms resulted in the identification of new pharmacological targets. Applying novel trial designs, targeting of pre-symptomatic disease stages, and the acknowledgment of PD heterogeneity raise hopes to overcome past failures in the development of drugs for disease modification. In this review, we address these recent developments and venture a glimpse into the future of PD therapy in the years to come.

show abstract

Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysis

Cited by 65 publications

References 0 publications

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Association between sex, systemic iron variation and probability of Parkinson's disease

Parkinson’s disease therapy: what lies ahead?

Contact Info

Product

Resources

About